OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a leading developer of biopharmaceutical compounds designed to treat cancer and certain ophthalmologic diseases, today announced it received regulatory clearance in the United Kingdom to commence its first Phase III clinical trial with its lead product candidate, Combretastatin A4P (CA4P). The Company will evaluate CA4P in combination with radiotherapy and chemotherapy for the treatment of unresectable Stage IIIb/IV NSCLC.
